Literature DB >> 24338004

GAP-independent functions of DLC1 in metastasis.

David Barras1, Christian Widmann.   

Abstract

Metastases are responsible for most cancer-related deaths. One of the hallmarks of metastatic cells is increased motility and migration through extracellular matrixes. These processes rely on specific small GTPases, in particular those of the Rho family. Deleted in liver cancer-1 (DLC1) is a tumor suppressor that bears a RhoGAP activity. This protein is lost in most cancers, allowing malignant cells to proliferate and disseminate in a Rho-dependent manner. However, DLC1 is also a scaffold protein involved in alternative pathways leading to tumor and metastasis suppressor activities. Recently, substantial information has been gathered on these mechanisms and this review is aiming at describing the potential and known alternative GAP-independent mechanisms allowing DLC1 to impair migration, invasion, and metastasis formation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24338004     DOI: 10.1007/s10555-013-9458-0

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  20 in total

1.  Down-regulation of DLC1 in endothelial cells compromises the angiogenesis process.

Authors:  Yi-Ping Shih; Sarah Y Yuan; Su Hao Lo
Journal:  Cancer Lett       Date:  2017-04-10       Impact factor: 8.679

2.  Deciphering the Molecular and Functional Basis of RHOGAP Family Proteins: A SYSTEMATIC APPROACH TOWARD SELECTIVE INACTIVATION OF RHO FAMILY PROTEINS.

Authors:  Ehsan Amin; Mamta Jaiswal; Urszula Derewenda; Katarina Reis; Kazem Nouri; Katja T Koessmeier; Pontus Aspenström; Avril V Somlyo; Radovan Dvorsky; Mohammad R Ahmadian
Journal:  J Biol Chem       Date:  2016-08-01       Impact factor: 5.157

Review 3.  Fixing the GAP: The role of RhoGAPs in cancer.

Authors:  Gabriel Kreider-Letterman; Nicole M Carr; Rafael Garcia-Mata
Journal:  Eur J Cell Biol       Date:  2022-02-10       Impact factor: 6.020

4.  Flavone inhibits migration through DLC1/RhoA pathway by decreasing ROS generation in breast cancer cells.

Authors:  Wenzhen Zhu; Long Ma; Bingwu Yang; Zhaodi Zheng; Rongfei Chai; Tingting Liu; Zhaojun Liu; Taiyu Song; Fenglin Li; Guorong Li
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-03-02       Impact factor: 2.416

5.  A WXW motif is required for the anticancer activity of the TAT-RasGAP317-326 peptide.

Authors:  David Barras; Nadja Chevalier; Vincent Zoete; Rosemary Dempsey; Karine Lapouge; Monilola A Olayioye; Olivier Michielin; Christian Widmann
Journal:  J Biol Chem       Date:  2014-07-09       Impact factor: 5.157

6.  Involvement of Rho GAP GRAF1 in maintenance of epithelial phenotype.

Authors:  Miriam Regev; Helena Sabanay; Elena Kartvelishvily; Zvi Kam; Alexander D Bershadsky
Journal:  Cell Adh Migr       Date:  2016-09-02       Impact factor: 3.405

7.  MicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1.

Authors:  Guang-jun Zhang; Jian-shui Li; He Zhou; Hua-xu Xiao; Yu Li; Tong Zhou
Journal:  J Exp Clin Cancer Res       Date:  2015-07-30

8.  Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.

Authors:  Yuqi Su; Li Lin; Jingwen Zhang; Yaqi Jiang; Changqie Pan; Li Sun; Jiangman Duan; Wangjun Liao
Journal:  Mol Med Rep       Date:  2015-08-03       Impact factor: 2.952

9.  Aberrant DNA methylation of alternative promoter of DLC1 isoform 1 in meningiomas.

Authors:  M Bujko; P Kober; N Rusetska; M Wakuła; K Goryca; E Grecka; E Matyja; J Neska; T Mandat; W Bonicki; J A Siedlecki
Journal:  J Neurooncol       Date:  2016-09-10       Impact factor: 4.130

10.  High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer.

Authors:  Jose A Guerrero-Martínez; Jose C Reyes
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.